Durable cell and gene therapies are poised for rapid growth - potentially providing transformative benefits for patients and exacerbating financial challenges for payers, providers, patients, and therapeutic developers. With five durable cell and gene therapies currently approved by the FDA, the FoCUS Pipeline Analysis Model expects 50-75 approvals over the next decade1 . These durable therapies are administered in a ‘one-time’ treatment course yielding multi-year, possibly lifetime, benefits for patients and ensuring improvements for their families, communities and healthcare systems.
Share this Post